| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Molecular Targeting and Polymer Toxicology Group, School of Pharmacy, University of Brighton, Brighton, UK; and
Cancer Research UK, Tumour Cytokine Biology Group, Wolfson Digestive Diseases Centre, University Hospital, Nottingham, UK
1Correspondence: Molecular Targeting and Polymer Toxicology Group, School of Pharmacy, University of Brighton, Brighton BN2 4GJ, UK. E-mail: s.m.moghimi{at}brighton.ac.uk;
Applications of nanotechnology for treatment, diagnosis, monitoring, and control of biological systems has recently been referred to as "nanomedicine" by the National Institutes of Health. Research into the rational delivery and targeting of pharmaceutical, therapeutic, and diagnostic agents is at the forefront of projects in nanomedicine. These involve the identification of precise targets (cells and receptors) related to specific clinical conditions and choice of the appropriate nanocarriers to achieve the required responses while minimizing the side effects. Mononuclear phagocytes, dendritic cells, endothelial cells, and cancers (tumor cells, as well as tumor neovasculature) are key targets. Today, nanotechnology and nanoscience approaches to particle design and formulation are beginning to expand the market for many drugs and are forming the basis for a highly profitable niche within the industry, but some predicted benefits are hyped. This article will highlight rational approaches in design and surface engineering of nanoscale vehicles and entities for site-specific drug delivery and medical imaging after parenteral administration. Potential pitfalls or side effects associated with nanoparticles are also discussed.—Moghimi, S. M. Hunter, A. C., Murray, J. C. Nanomedicine: current status and future prospects.
Key Words: nanotechnology • nanosized drug delivery systems • nanoparticles • medical imaging • gene therapy • nanofibers • macrophage • endothelium • intracellular delivery • extravasation • toxicity
This article has been cited by other articles:
|
|
 |
|
  U. Zimmerli and P. Koumoutsakos Simulations of Electrophoretic RNA Transport Through Transmembrane Carbon Nanotubes Biophys. J., April 1, 2008; 94(7): 2546 - 2557. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Bendz, S. C. Ruhland, M. J. Pandya, O. Hainzl, S. Riegelsberger, C. Brauchle, M. P. Mayer, J. Buchner, R. D. Issels, and E. Noessner Human Heat Shock Protein 70 Enhances Tumor Antigen Presentation through Complex Formation and Intracellular Antigen Delivery without Innate Immune Signaling J. Biol. Chem., October 26, 2007; 282(43): 31688 - 31702. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Ryan, H. R. Bateman, A. Stover, G. Gomez, S. K. Norton, W. Zhao, L. B. Schwartz, R. Lenk, and C. L. Kepley Fullerene Nanomaterials Inhibit the Allergic Response J. Immunol., July 1, 2007; 179(1): 665 - 672. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Yang Nano- and Microparticle-based Imaging of Cardiovascular Interventions: Overview Radiology, May 1, 2007; 243(2): 340 - 347. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Moghimi, I. Hamad, T. L. Andresen, K. Jorgensen, and J. Szebeni Methylation of the phosphate oxygen moiety of phospholipid-methoxy(polyethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production FASEB J, December 1, 2006; 20(14): 2591 - 2593. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-W. Chen, S.-F. Su, C.-T. Chien, W.-H. Lin, S.-L. Yu, C.-C. Chou, J. J. W. Chen, and P.-C. Yang Titanium dioxide nanoparticles induce emphysema-like lung injury in mice FASEB J, November 1, 2006; 20(13): 2393 - 2395. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Pandey and G. K. Khuller Oral nanoparticle-based antituberculosis drug delivery to the brain in an experimental model J. Antimicrob. Chemother., June 1, 2006; 57(6): 1146 - 1152. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
